Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 20/20 | 0.76 |
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.76 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | ACTR3 | P61158 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1488975 | 1.00 | MAP2K2 (0.76) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL1488459 | 0.92 | MAP2K2 (0.75) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL30220957 | 0.92 | MAP2K2 (0.75) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL1488271 | 0.90 | MAP2K2 (0.80) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL30220870 | 0.90 | MAP2K2 (0.80) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL29413639 | 0.90 | MAP2K2 (0.80) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL189265 | 0.90 | MAP2K2 (0.80) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL1488242 | 0.90 | MAP2K2 (0.82) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL29413607 | 0.90 | MAP2K2 (0.82) | MAP2K2MAP2K1BRAFCHRM2CHRM1 | |
| SCHEMBL1489061 | 0.89 | MAP2K2 (0.83) | MAP2K2MAP2K1BRAFCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | MAP2K2 51/4885MAP2K1 53/4885BRAF 1/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | MAP2K2 49/4885MAP2K1 52/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.